Observational analysis finds lower medical costs in overweight patients treated with semaglutide, indicating its value in healthcare resource utilization.
Key Points
Lower medical costs were associated with semaglutide treatment in patients with obesity, suggesting economic benefits.
Patients treated with semaglutide showed a significant reduction in healthcare resource utilization compared to those not treated.
The analysis focused on the real world setting, ensuring findings reflect typical medical practices and costs.
Implications of these findings highlight the potential for semaglutide to contribute to overall cost savings in obesity management.